| Title |
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression
|
|---|---|
| Published in |
Cancer and Metastasis Reviews, September 2010
|
| DOI | 10.1007/s10555-010-9256-x |
| Pubmed ID | |
| Authors |
Xueqing Sun, Guangcun Cheng, Mingang Hao, Jianghua Zheng, Xiaoming Zhou, Jian Zhang, Russell S. Taichman, Kenneth J. Pienta, Jianhua Wang |
| Abstract |
Chemokines, small pro-inflammatory chemoattractant cytokines that bind to specific G-protein-coupled seven-span transmembrane receptors, are major regulators of cell trafficking and adhesion. The chemokine CXCL12 (also called stromal-derived factor-1) is an important α-chemokine that binds primarily to its cognate receptor CXCR4 and thus regulates the trafficking of normal and malignant cells. For many years, it was believed that CXCR4 was the only receptor for CXCL12. Yet, recent work has demonstrated that CXCL12 also binds to another seven-transmembrane span receptor called CXCR7. Our group and others have established critical roles for CXCR4 and CXCR7 on mediating tumor metastasis in several types of cancers, in addition to their contributions as biomarkers of tumor behavior as well as potential therapeutic targets. Here, we review the current concepts regarding the role of CXCL12 / CXCR4 / CXCR7 axis activation, which regulates the pattern of tumor growth and metastatic spread to organs expressing high levels of CXCL12 to develop secondary tumors. We also summarize recent therapeutic approaches to target these receptors and/or their ligands. |
Mendeley readers
The data shown below were compiled from readership statistics for 546 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 6 | 1% |
| Poland | 2 | <1% |
| Japan | 2 | <1% |
| United Kingdom | 2 | <1% |
| France | 1 | <1% |
| Italy | 1 | <1% |
| Netherlands | 1 | <1% |
| Brazil | 1 | <1% |
| Unknown | 530 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 119 | 22% |
| Student > Master | 84 | 15% |
| Researcher | 76 | 14% |
| Student > Bachelor | 71 | 13% |
| Student > Doctoral Student | 38 | 7% |
| Other | 89 | 16% |
| Unknown | 69 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 138 | 25% |
| Biochemistry, Genetics and Molecular Biology | 104 | 19% |
| Medicine and Dentistry | 95 | 17% |
| Chemistry | 32 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 31 | 6% |
| Other | 61 | 11% |
| Unknown | 85 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 23. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2022.
All research outputs
#1,477,931
of 23,563,389 outputs
Outputs from Cancer and Metastasis Reviews
#20
of 829 outputs
Outputs of similar age
#5,015
of 97,208 outputs
Outputs of similar age from Cancer and Metastasis Reviews
#2
of 17 outputs
Altmetric has tracked 23,563,389 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 93rd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 829 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.3. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 97,208 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.